Exciting time in MASLD, lots of emerging compounds.
One to know => survodutide
➡️ GLPRA/Glucagon agonist
➡️ unlike GLP, liver has glucagon receptors so survodutide acts directly on the liver
➡️ SYNCHRONIZE-MASLD 2026
- MASLD pts defined by MRI (~90%) likely with F0-2
- survodutide met co-primary endpoints
1. 84% had =>30% reduction in liver fat